Ardent Health Partners Names Dave Caspers as COO-February 2024-www.financetom.com

Ardent Health Partners Names Dave Caspers as COO

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Ardent Health Partners Names Dave Caspers as COO

Mar 31, 2025 2:47 PM

05:18 PM EDT, 03/31/2025 (MT Newswires) -- Ardent Health Partners ( ARDT ) appointed Dave Caspers as chief operating officer, effective immediately.

Since October 2023, Caspers served as the chief stores officer of Leslie's (LESL), Ardent said Monday in a regulatory filing.

Previous page： Dick's Sporting Goods Q3 EPS Forecast Raised on 'Modestly Stronger' Comparable Store Sales Growth, Oppenheimer Says Next page： Novartis Says Talks for Prostate Cancer Treatment Close Without Deal

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Dick's Sporting Goods Q3 EPS Forecast Raised on 'Modestly Stronger' Comparable Store Sales Growth, Oppenheimer Says

Nov 15, 2024

11:54 AM EST, 11/15/2024 (MT Newswires) -- Dick's Sporting Goods (DKS) fiscal Q3 earnings per share are now expected to be $2.72 driven by expectations of modestly stronger comparable store sales growth of 2% to 4%, up from 1% to 3%, Oppenheimer said in an earnings preview Friday. Oppenheimer's previous EPS estimate for Dick's Sporting Goods, which is set to...

Novartis Says Talks for Prostate Cancer Treatment Close Without Deal

Nov 15, 2024

11:51 AM EST, 11/15/2024 (MT Newswires) -- Novartis (NVS) unit Novartis Pharmaceuticals Canada said Friday that negotiations with the pan-Canadian Pharmaceutical Alliance for Pluvicto, a treatment for patients with a certain type of prostate cancer, have closed without an agreement. This outcome is a significant setback for people living with [metastatic castration-resistant prostate cancer] whose cancer is progressing despite standard...

Global Dividend Growth Split Corp Renewing At-The-Market Equity Program

Nov 15, 2024

11:53 AM EST, 11/15/2024 (MT Newswires) -- Global Dividend Growth Split Corp (GDV.TO) on Friday said it renewed its at-the-market equity program (ATM program). Sales of Class A and preferred shares will be made by at-the-market distributions. The maximum gross proceeds from the issue of the shares will be $100 million each for Class A and preferred share. The company...

Barinthus Biotherapeutics Reports 'Encouraging' Phase 2b HBV003 Trial Results for Chronic Hepatitis B

Nov 15, 2024

12:29 PM EST, 11/15/2024 (MT Newswires) -- Barinthus Biotherapeutics ( BRNS ) on Friday reported encouraging results from its ongoing phase 2b HBV003 trial for chronic hepatitis B. The study, involving 121 participants, assessed VTP-300 in combination with a low dose of anti-PD1 antibody nivolumab, and new data shows eight participants achieved complete HBsAg loss, while two met the criteria...